Flush With Cash And Partnered Up, Regulus Turns To Clinical Execution: An Interview With CEO Kleanthis Xanthopoulos
Regulus notched two partnerships and an IPO in 2012, putting it on firmer financial ground. Now, as it transitions to executing on its partnerships and pushing ahead with its internal programs, its task is to demonstrate the clinical utility of its miRNA compounds.
You may also be interested in...
Plus the latest financing news from Denmark’s Symphogen, ScioDerm, Esperion Therapeutics and Intrexon.
Genzyme said it is ready to deliver product, but complying with the REMS that helped pave the way for approval is a time-limiting factor for launching the familial hypercholesterolemia drug. Drug will be priced at $176,000 per year, significantly lower than Aegerion’s competing Juxtapid.
Alnylam’s release of early-stage clinical data for its lead amyloidosis project in July caused a surge in its market value and rare cheers from investors. Years removed from its most recent high-profile technology deal, Alnylam is a company on the verge of completing the trickiest metamorphosis in biotech: from technology platform to product focus without the benefit of transformational M&A.